Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model

This article was originally published in PharmAsia News

Executive Summary

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding

You may also be interested in...



Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

Chinese-U.S. hybrid MicuRx, founded by Vicuron veterans, has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.

China Sees Increasing Appetite For Innovative Products – PharmAsia Summit

China's life sciences industry is at a crossroads, and new commercial models are needed to drive future growth, but a disconnect between corporate strategies may derail execution.

U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina

U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina

Related Content

UsernamePublicRestriction

Register

PS141439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel